Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
adult, AEs, alanine, ALT, aminotransferase, analyze, antifibrotic, aspartate, assist, assistance, AST, attain, baseline, biopsy, Building, burden, CAD, cohort, collagen, collected, committed, concept, daily, DDI, declared, degradation, detailed, doubt, ELF, elicit, endpoint, enroll, enrolled, ensure, environment, FibroScan, forfeiture, formal, health, healthy, hepatic, HepQuant, identification, imaging, implement, implementation, implementing, Interaction, justify, kidney, landlord, Liquidity, listing, low, matching, maximum, mechanism, mg, mild, moderate, Nasdaq, negotiating, paired, paragraph, party, permitted, PK, plain, procedure, profile, proof, proper, provision, quickly, randomized, recommend, remedial, remediating, remediation, requisite, retrospectively, royalty, SAB, SAD, satisfy, score, screening, sensitive, Shunt, sourced, supplement, timeline, training, unaware, uncapped, unrelated, vanilla
Removed:
absolute, accretion, achieving, aforementioned, applied, assurance, ASU, beginning, beneficial, borrowing, call, CFO, deemed, deliver, Description, detect, detected, director, disruption, Emerging, Entity, error, evident, FASB, feature, fraud, Freestanding, hand, incremental, individual, Issuer, leading, marked, matter, measuring, minimum, noncancelable, obligated, operated, outbreak, participation, point, predicted, proceed, professional, prospective, registered, relate, rental, standard, Subtopic, suggest, summarized, supervision, system, Task, twelve, understood, warrant, Wijngaard
Filing tables
Filing exhibits
HEPA similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
HEPION PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2023
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I am the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended March 31, 2023 and filed with the Securities and Exchange Commission (“Form 10-Q”).
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 12, 2023 | /s/ Robert Foster | ||||
Robert Foster | |||||
Chief Executive Officer and Director | |||||
(Principal Executive Officer) |